The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...
The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The drug is for moderate to severe acute pain. The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.
With the announcement of this new FDA-approved pain medication comes a new class of pain relief that bypasses these dangers. Unlike opioids, which work by dulling pain perception in the brain ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.
During “Real Possibilities with AARP Michigan,” Dr. Joshua P. June from the Great Lakes Center of Rheumatology shares tips ...
All three cannabinoids reduced the electrical activity linked to Nav1.8, but CBG had the strongest effect. This suggests that CBG could be the most promising candidate for developing new pain ...